AIFF vs PHG vs NEOG Stock Comparison

Firefly Neuroscience, Koninklijke Philips and Neogen Prices as of Oct 27, 2026 Peers: Industry group
PHG Koninklijke Philips Nv
$26.42 +5.8% 1M -8.5% 1Y
Market cap
$25.44B
P/E
13.6x
Revenue (TTM)
$20.60B
Div. yield
3.75%
Diagnostic Equipment Healthcare
8 wins
NEOG Neogen Corp
$12.47 -9.4% 1M +100.8% 1Y
Market cap
$2.72B
P/E
–
Revenue (TTM)
$883.99M
Div. yield
–
Diagnostic Equipment Healthcare
1 win

Head to Head

10 decided of 12

Koninklijke Philips leads on 8 of the 12 questions below (Koninklijke Philips 8, Firefly Neuroscience 1, Neogen 1). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionAIFFPHGNEOGLeader
Larger companyMarket capitalisation $20.58M $25.44B $2.72B PHG
Cheaper on earningsLower P/E, profitable companies only -2.2x 13.6x -48.5x –
Cheaper on forward earningsLower price / next fiscal year consensus EPS — 13.3x 39.0x PHG
Faster revenue growthRevenue growth, trailing twelve months +320.3% +6.1% -0.3% AIFF
More profitableNet margin, trailing twelve months -524.5% 8.9% -6.3% PHG
Better return on capitalReturn on invested capital — 11.5% -0.2% PHG
Less leveragedLower net debt / EBITDA — 1.8x 5.4x PHG
Higher dividend yieldTrailing dividend yield — 3.75% — –
Better 1-year returnPrice return, last 12 months -50.7% -8.5% +100.8% NEOG
Better 5-year returnAnnualised price return, 5 years -60.6%/yr -11.1%/yr -21.4%/yr PHG
Less volatileAnnualised volatility, 1 year 159.8% 28.7% 55.6% PHG
Higher overall scoreMean of the five percentile scores vs peers 38/100 80/100 58/100 PHG

Percentile Scorecard

AIFFPHGNEOG

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisAIFFPHGNEOG
Valuation 15 #194 of 227 98 #6 of 227 71 #66 of 227
Growth 61 #86 of 219 95 #11 of 219 50 #110 of 219
Profitability 15 #176 of 206 95 #11 of 206 62 #79 of 206
Financial Health 80 #49 of 238 31 #165 of 238 46 #128 of 238
Shareholder Returns 20 #107 of 134 79 #29 of 134 58 #57 of 134
Overall 38 80 58
  • AIFF ranked among 247 companies in Medical Devices and Diagnostics
  • PHG ranked among 247 companies in Medical Devices and Diagnostics
  • NEOG ranked among 247 companies in Medical Devices and Diagnostics

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodAIFFPHGNEOGSPY
1 month -50.2%+5.8%-9.4% -0.2%
3 months -9.9%+3.4%+35.7% +3.9%
6 months -52.8%-2.6%+33.5% +8.2%
Year to date +13.6%-2.4%+78.4% +12.9%
1 year -50.7%-8.5%+100.8% +12.3%
3 years -82.6%+42.8%-18.6% +87.4%
3 years, per year -44.2%+12.6%-6.6% +23.3%
5 years -99.0%-44.3%-69.9% +67.9%
5 years, per year -60.6%-11.1%-21.4% +10.9%
10 years -77.8%-11.3%-35.8% +261.1%
10 years, per year -14.0%-1.2%-4.3% +13.7%

Risk

MeasureAIFFPHGNEOGSPY
Volatility, 1Y 159.8%28.7%55.6% 12.7%
Downside volatility, 1Y 109.1%28.7%46.5% 12.7%
Beta vs S&P 500, 1Y 1.520.811.45 1.00
Return / volatility, 1Y -0.32-0.301.81 0.97
Max drawdown, 5Y -99.6%-75.6%-90.6% -25.4%
From 52-week high -66.9%-19.7%-10.8% -1.2%
52-week high $3.02$32.91$13.98 $779.14
52-week low $0.64$23.81$5.41 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleAIFFPHGNEOG
P/E now vs peer median -2.2xmedian 29.6x 13.6xmedian 29.6x -48.5xmedian 29.6x
P/S now vs peer median 11.4xmedian 2.9x 1.2xmedian 2.9x 3.1xmedian 2.9x
EV/EBITDA now vs peer median -1.3xmedian 17.4x 8.1xmedian 17.4x 30.0xmedian 17.4x
P/FCF now vs peer median -2.9xmedian 22.3x 5.9xmedian 22.3x 54.7xmedian 22.3x
P/B now vs peer median 1.4xmedian 2.3x 1.9xmedian 2.3x 1.3xmedian 2.3x
PEG now vs peer median -0.03median 1.04 0.32median 1.04 1.73median 1.04

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsAIFFPHGNEOG
Revenue $1.80M $20.60B $883.99M
Gross profit $802.00K $16.03B $418.98M
Operating income -$9.14M $2.65B -$7.38M
Net income -$9.11M $1.39B -$56.10M
Free cash flow -$7.20M $4.34B $49.80M
R&D $1.78M $2.00B $19.76M
EPS (diluted) $-0.70 $1.91 $-0.26
Cash & equivalents $9.23M $2.04B $172.00M
Total debt – $9.51B $774.20M
Shares (diluted) 13.50M 962.50M 218.10M
Enterprise value $1.15M $14.59B $2.06B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricAIFFPHGNEOG
P/E -2.2x 13.6x -48.5x
P/FCF -2.9x 5.9x 54.7x
P/Operating cash flow -2.9x 9.6x 31.9x
P/S 11.4x 1.2x 3.1x
P/B 1.4x 1.9x 1.3x
P/Tangible book 1.5x 2.5x 3.4x
EV/EBITDA -1.3x 8.1x 30.0x
EV/EBIT -1.2x 12.4x -450.7x
EV/Revenue 6.3x 1.6x 3.8x
EV/FCF -1.6x 7.6x 66.8x
EV/Operating cash flow -1.6x 12.4x 39.0x
PEG (3Y EPS CAGR) -0.03 0.32 1.73

Growth

14 metrics
MetricAIFFPHGNEOG
Revenue growth (1Y) 320.3% 6.1% -0.3%
Revenue CAGR (3Y) -40.3% 2.3% -1.3%
Gross profit growth (1Y) 99.0% 82.4% 1.8%
Gross profit CAGR (3Y) -32.6% 6.7% -3.1%
Operating income growth (1Y) 19.8% 121.3% 99.3%
Operating income CAGR (3Y) -52.0% 52.0% -29.0%
Net income growth (1Y) 60.1% 293.5% 94.6%
Net income CAGR (3Y) 15.8% 35.6% -28.3%
EPS growth (1Y) 81.8% 539.4% 94.6%
EPS CAGR (3Y) 69.0% 42.2% -28.0%
Operating cash flow growth (1Y) 19.1% 116.7% -1.9%
Operating cash flow CAGR (3Y) -8.4% 53.6% 2.9%
Free cash flow growth (1Y) 17.6% 54.2% 1,631%
Free cash flow CAGR (3Y) -6.3% 45.6% 126.1%

Profitability

14 metrics
MetricAIFFPHGNEOG
Gross margin 44.6% 77.8% 47.4%
EBITDA margin -496.9% 19.8% 12.5%
Operating margin -508.1% 12.9% -0.8%
Pretax margin -506.2% 11.9% -7.7%
Net margin -524.5% 8.9% -6.3%
FCF margin -400.2% 21.1% 5.6%
Operating cash flow margin -388.6% 12.9% 9.6%
Return on equity -78.8% 12.7% -2.7%
Return on assets -65.8% 5.4% -1.7%
Return on invested capital – 11.5% -0.2%
Return on capital employed -77.9% 11.8% -0.2%
Asset turnover 0.1x 0.7x 0.3x
Cash conversion (OCF / net income) 0.8x 1.9x -1.5x
Stock comp / revenue 36.4% 0.7% 1.3%

Financial Health

11 metrics
MetricAIFFPHGNEOG
Debt / assets – 31.2% 23.4%
Debt / equity – 0.7x 0.4x
Net debt / EBITDA – 1.8x 5.4x
Debt / FCF – 2.2x 15.5x
Liabilities / assets 12.6% 57.1% 36.8%
Equity / assets 87.4% 42.9% 63.2%
Interest coverage – 6.2x –
Current ratio 4.9x 1.3x 3.9x
Quick ratio 4.5x 0.7x 2.1x
Cash ratio 4.4x 0.2x 1.2x
Altman Z-score -4.89 – 1.52

Shareholder Returns

7 metrics
MetricAIFFPHGNEOG
Dividend yield – 3.7% –
Net buyback yield -2.0% -0.5% -0.1%
Shareholder yield -2.0% 3.3% -0.1%
Payout ratio (earnings) – – –
Payout ratio (FCF) – – –
Dividend growth (1Y) – – –
Dividend CAGR (3Y) – – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusAIFFPHGNEOG
Forward P/E – 13.3xFY2026 39.0xFY2026
EPS, next fiscal year – $1.98FY2026 $0.32FY2026
EPS growth, next FY – +6.5%FY2026 0.0%FY2026
EPS growth, the year after – -10.1% +31.3%
Revenue, next fiscal year – $21.63BFY2026 $847.28MFY2026
Revenue growth, next FY – +1.8%FY2026 -2.7%FY2026
Revenue growth, the year after – -8.2% -1.5%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersAIFFPHGNEOG
Held by institutions 7.9% 5.4% 100.0%
Institutions holding 23 363 315
Change in shares held, QoQ +34.3% +0.8% +1.6%
Institutions buying 10 266 151
Institutions selling 6 76 106
Buyers to sellers 1.67 3.50 1.42

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

AIFFPHGNEOG
AIFF 1.00 0.06 0.08
PHG 0.06 1.00 0.31
NEOG 0.08 0.31 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, AIFF, PHG and NEOG?

Koninklijke Philips (PHG) is the largest by market capitalisation: Firefly Neuroscience (AIFF) $20.58M, Koninklijke Philips (PHG) $25.44B, Neogen (NEOG) $2.72B.

Which company is growing faster?

Firefly Neuroscience (AIFF) grew revenue fastest over the trailing twelve months: Firefly Neuroscience (AIFF) +320.3%, Koninklijke Philips (PHG) +6.1%, Neogen (NEOG) -0.3%.

Which company is more profitable?

Koninklijke Philips (PHG) has the highest net margin (Firefly Neuroscience (AIFF) -524.5%, Koninklijke Philips (PHG) 8.9%, Neogen (NEOG) -6.3%). On return on invested capital, Koninklijke Philips (PHG) leads (Koninklijke Philips (PHG) 11.5%, Neogen (NEOG) -0.2%).

Which stock has performed better?

Over the past year Neogen (NEOG) returned the most: Firefly Neuroscience (AIFF) -50.7%, Koninklijke Philips (PHG) -8.5%, Neogen (NEOG) +100.8%. Over five years, Koninklijke Philips (PHG) compounded fastest (Firefly Neuroscience (AIFF) -60.6%/yr, Koninklijke Philips (PHG) -11.1%/yr, Neogen (NEOG) -21.4%/yr). Returns are price only, before dividends.

Which pays a higher dividend?

Only one of these companies pays a dividend: Koninklijke Philips (PHG) 3.75%. Firefly Neuroscience (AIFF) and Neogen (NEOG) pays no regular dividend.

Which stock is riskier?

By one-year price volatility, Koninklijke Philips (PHG) has been the steadiest (Firefly Neuroscience (AIFF) 159.8%, Koninklijke Philips (PHG) 28.7%, Neogen (NEOG) 55.6%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, AIFF, PHG and NEOG?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Koninklijke Philips (PHG) leads on 8. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.